|Bid||3.3400 x 2200|
|Ask||3.7300 x 1100|
|Day's range||3.2000 - 3.5100|
|52-week range||2.1300 - 22.6800|
|Beta (5Y monthly)||1.94|
|PE ratio (TTM)||N/A|
|Earnings date||31 Oct 2022 - 04 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.72|
An analyst had a fresh new take on the company's prospects, and it wasn't all that positive.
ROCKVILLE, MD, Sept. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in September 2022: Citi 17th Annual BioPharma Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in the Bispecifi
Shareholders in MacroGenics, Inc. ( NASDAQ:MGNX ) may be thrilled to learn that the analysts have just delivered a...